Changeflow GovPing Pharma & Drug Safety Methods for Producing Highly Purified (R)-3-Hyd...
Routine Notice Added Final

Methods for Producing Highly Purified (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate for Enhancing Bodily Function and Treating Disease States

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260098281A1 by Romeo Tango, LLC for methods of producing highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. The application covers therapeutic applications including inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additional applications include improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection.

What changed

USPTO published patent application US20260098281A1 covering methods for producing highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and its use for enhancing bodily function and treating disease states. The application describes production processes external to the human body and administration methods for achieving therapeutic benefits including inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, promoting muscle protein synthesis, improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection.

Pharmaceutical companies and biotechnology firms should monitor this patent application for potential licensing opportunities or competitive implications in the metabolic health, anti-inflammatory, and neuroprotective therapeutic spaces. Inventors Daryl Richard Sauer and Carl Edward Sheeley, Jr. filed application number 19347997 on October 2, 2025.

What to do next

  1. Monitor for updates on patent examination status
  2. Review claims for potential licensing or competitive implications

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS FOR PRODUCING HIGHLY PURIFIED (R)-3’-HYDROXYBUTYL (R)-3’-HYDROXYBUTYRATE AND USE FOR ENHANCING BODILY FUNCTION AND TREATING DISEASE STATES

Application US20260098281A1 Kind: A1 Apr 09, 2026

Assignee

Romeo Tango, LLC

Inventors

Daryl Richard Sauer, Carl Edward Sheeley, JR.

Abstract

The present disclosure relates to highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate and biomedical uses thereof. In particular highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate, is provided for enhancing bodily function and treating various disease states. The methods described herein provide for production of a highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate via processes external to the human body and administering effective amounts of highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate to human subjects to achieve a range of therapeutic benefits, including but not limited to, one or more of: inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additionally, highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate is administered in an amount and frequency conducive to one or more of: improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection. Methods for manufacturing and purifying (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate compositions to ensure high specificity and efficacy in therapeutic applications are also provided.

CPC Classifications

C12P 7/62 A61K 31/22 C12N 9/18 C12N 11/087 C12Y 301/01003 G01N 30/72 G01N 2030/025

Filing Date

2025-10-02

Application No.

19347997

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260098281A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Pharmaceutical manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!